Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study

Maria, Giorgio; Brisinda, Giuseppe; Im, Civello; Bentivoglio, Anna Rita; Sganga, Gabriele; Albanese, Alberto

doi:10.1016/s0090-4295(03)00477-1

Cited by 212 publications

(158 citation statements)

References 26 publications

Supporting

Mentioning

132

Contrasting

Unclassified

Order By: Relevance

“…These findings have subsequently been confirmed in human subjects 17 resulting in a 30-50% reduction 18 in prostate weight. Prostate biopsies obtained from human prostates after Botox injection revealed numerous apoptotic cells in 18 .…”

Section: Botoxmentioning

confidence: 54%

The Minimally Invasive Treatments for Benign Prostrate Hyperplasia

Lim

Tay

2014

Proceedings of Singapore Healthcare

View full text Add to dashboard Cite

The prevalence of benign prostatic hyperplasia (BPH) increases with age, affecting more than 50% of men above the age of 50 to varying degrees. As it enlarges, it compresses onto the urethra causing bladder outlet obstruction. This can cause a spectrum of problems ranging from irritative and obstructive lower urinary tract symptoms (LUTS) to retention of urine with obstructive uropathy. Transurethral resection of prostate (TURP) is the standard for surgical intervention, however with the advent of an ageing population, there is an increasing number of patients who have ischaemic heart disease who require long-term anticoagulation and have multiple co-morbidities that put them at an increased risk of general anaesthesia. This review aims to critically appraise the effectiveness and evidence for use of these minimally invasive techniques.Both PubMed and Ovid were used to search for randomised control trials (RCT) comparing the various minimally invasive techniques against TURP. In cases where there were no RCTs, the results of the respective trial were compiled. This was later compiled in a summary table.An effective minimally invasive treatment modality will play a complimentary role to TURP which remains the standard of surgical treatment for BPH. Technologies progressing towards rapid re-creation of prostatic channel, minimal blood loss and non-urethral instrumentation will bridge the divide between pharmacotherapy and surgery.

show abstract

Section: Botoxmentioning

confidence: 54%

The Minimally Invasive Treatments for Benign Prostrate Hyperplasia

Lim

Tay

2014

Proceedings of Singapore Healthcare

View full text Add to dashboard Cite

show abstract

“…In a prospective, randomized, placebo-controlled, double-blind trial conducted by Maria et al (43), which supports the therapeutic properties of BoNT-A in BPH, 200 IU BoNT-A was intraprostatically injected to 15 patients in 4 mL saline,. The procedure was performed using the transrectal ultrasound guideline perineally with 2 mL per prostate lobe.…”

Section: -Benign Prostatic Hyperplasiamentioning

confidence: 81%

Use of botulinum toxin in urology: a literature review

Bayrak¹,

Şeçkiner²,

Onur³

et al. 2018

Eur J Ther

View full text Add to dashboard Cite

Botulinum neurotoxin (BoNT) is currently preferred as a minimally invasive treatment for lower urinary tract pathologies. Although BoNT injections have become widespread globally for the past 5 years, today, the urological use of BoNT Type A (BoNT-A) is only licensed for the treatment of neurogenic detrusor overactivity and overactive bladder. Despite the relative evidence for the use of BoNT-A in benign prostatic enlargement, there is no high-level evidence data for the use in detrusor sphincter dyssynergia, interstitial cystitis/bladder pain syndrome, and chronic pelvic pain. In this comprehensive review, we mention the mechanism of action and efficacy of BoNT in various urological disorders, present the reliability, and evaluate the literature data supporting its use.

show abstract

“…Os resultados obtidos no presente estudo estão em concordância com os relatados por MARIA et al (2003) quanto à ocorrência de máxima depleção do volume prostático, após dois ou três meses da injeção de TB-A. Da mesma maneira, os dados aqui descritos estão de acordo com os mesmos autores, no que se refere ao período de efetividade da TB-A, onde estes apresentam declínio após quatro a seis meses.…”

Section: Discussionunclassified

“…Em homens, a administração de TB-A, intraprostaticamente, tem propiciado excelentes resultados, com uma rápida e segura redução do volume do órgão, além de ser adequada naqueles com riscos por problemas pré-existentes (MARIA et al, 2003;KUO, 2005). Entretanto, a influência dessa neurotoxina foi pouco estudada no cão, existindo poucos relatos de sua utilização (CHUANG et al 2006b;MOSTACHIO et al, 2012).…”

Section: Introductionunclassified

Administração de toxina botulínica A e a orquiectomia no tratamento da hiperplasia prostática benigna do cão

et al. 2015

View full text Add to dashboard Cite

RESUMO A fisiopatologia da hiperplasia prostática benigna (HPB) não está totalmente compreendida, no entanto, a diidrotestosterona é o principal hormônio envolvido. Recentemente, o efeito da toxina botulínica A (TB-A INTRODUÇÃODiante do aumento da expectativa de vida dos cães, problemas relacionados à próstata, especialmente a hiperplasia prostática benigna (HPB), vêm adquirindo importância. A etiologia da doença no cão é incerta, no entanto, pesquisas demonstraram que a próstata está sobre influência da inervação autonômica e aos seus neurotransmissores, sendo que a acetilcolina promove a estimulação do crescimento da próstata, assim, por essas razões, estudos têm confirmado que a toxina botulínica do tipo A (TB-A) é efetiva para controlar os componentes mecânicos e dinâmicos da HPB (DOGGWEILER et al., 1998;KUO, 2005).A orquiectomia é o tratamento de escolha para os cães acometidos pela enfermidade, no entanto, naqueles destinados à reprodução ou onde há contraindicação cirúrgica, a terapia conservativa é de grande importância. Em homens, a administração

show abstract

Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study

Cited by 212 publications

References 26 publications

The Minimally Invasive Treatments for Benign Prostrate Hyperplasia

The Minimally Invasive Treatments for Benign Prostrate Hyperplasia

Use of botulinum toxin in urology: a literature review

Administração de toxina botulínica A e a orquiectomia no tratamento da hiperplasia prostática benigna do cão

Contact Info

Product

Resources

About